Articles

Lenacapavir posts 100% HIV prevention in PURPOSE 1

Gilead’s lenacapavir posted 100% efficacy in the Phase 3 PURPOSE 1 trial for HIV prevention in cisgender women. The result strengthens the case for Lenacapavir PrEP and raises the stakes for Gilead’s next regulatory and clinical catalysts.

BMS ADEPT-2 Continues Cobenfy Alzheimer’s Trial

Bristol Myers Squibb’s Cobenfy has reached a key milestone in Alzheimer’s psychosis, expanding the story beyond its approved schizophrenia use. Analysts should watch ADEPT-2 execution, enrollment changes, and whether the signal supports a broader development path.

Eli Lilly Q1 sales blowout lifts 2026 guide

Eli Lilly’s latest quarter showed stronger-than-expected Mounjaro demand, prompting a higher 2026 revenue outlook. The update matters for analysts and BD teams tracking obesity-market momentum, trial catalysts, and next earnings milestones.

Strongest non opioid painkiller? Journavx facts

The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.

Novo Nordisk CagriSema Phase 3 Results: Obesity Catalyst Update

Novo Nordisk’s CagriSema phase 3 update shows strong obesity and diabetes efficacy, but the obesity readout fell short of top-tier expectations. This plan focuses on the catalyst, the comparator data, and what BD teams and investors should watch next.

Lenacapavir PrEP: PURPOSE 1 and 2 Efficacy

Gilead’s lenacapavir PrEP has emerged as a high-efficacy HIV prevention asset after Phase 3 results showed strong protection versus comparators. This plan focuses on what changed, why it matters for investors and BD teams, and the next catalysts to watch.

Non-Opioid Pain Meds: Journavx FDA Launch

Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.

AstraZeneca Daiichi Datopotamab Lung Endpoint

AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.

FDA Approved Gene Therapy List for Rare Disease

Only about 5% of rare diseases have an FDA-approved drug, but gene therapies are gaining ground. This analysis covers the latest FDA approved gene therapy list, including the recent approval of Kresladi for LAD-I, and what it means for pharma teams and investors.

Amneal Romidepsin FDA Approval Analysis

Amneal won FDA approval for ready-to-use romidepsin 27.5 mg/5.5 mL with 180-day CGT exclusivity for CTCL after prior systemic therapy.

Lilly Retatrutide Phase 3 Safety Profile

TRIUMPH-1: retatrutide 12 mg delivered 28.3% weight loss at 80 weeks with dose-related GI events and discontinuations up to 11.3%.

Summit Carbon Pipeline Iowa Outlook

Iowa approved Summit’s CO2 pipeline permit in June 2024, but South Dakota later denied a key segment. Ethanol SEC filings still cite 2027 targets.

McGuireWoods PE Healthcare M&A Counsel

PE keeps reshaping hospice and home-health deal flow. Campbell’s Emerging Leaders recognition sits against CMS data and SEC antitrust warnings.

Lundbeck Advances Lu AG09222 After Phase 2 Migraine Data

Lundbeck is advancing its PACAP-targeting migraine drug Lu AG09222 into Phase 3 after Phase 2 data showed efficacy in patients not helped by prior treatments. The decision signals confidence in a novel mechanism that could compete with CGRP inhibitors.

Revolution Medicines' Daraxonrasib: Pancreatic Cancer Breakthrough and Beyond

Daraxonrasib nearly doubled overall survival in a Phase III trial for pancreatic ductal adenocarcinoma, an unprecedented outcome. This article analyzes the clinical data, regulatory implications, and strategic impact for pharma BD and investors.

Celcuity Expands VIKTORIA-2 Trial as Shares Trade Below Analyst Targets

Celcuity has expanded its Phase 3 VIKTORIA-2 trial to include endocrine-sensitive HR+/HER2- advanced breast cancer patients. Despite the expansion, shares trade roughly 43% below the consensus analyst price target, signaling a potential value gap for investors and strategic partners.

FDA Flavored Vape Ban: Youth Risk and Pharma Implications

The FDA's evolving stance on flavored vapes and pouches, including recent authorizations of fruit-flavored e-cigarettes, raises renewed youth addiction risks. This analysis provides pharma strategists with a grounded view of regulatory changes, competitive implications, and next milestones.

Ebola Outbreak CDC Response: Bundibugyo 2026

The May 2026 Bundibugyo Ebola outbreak in DRC and Uganda triggered a CDC emergency response and a WHO PHEIC. Analysis for pharma BD teams using verified CDC and WHO numbers.

Listeria Outbreaks 2026: FDA and CDC Soft Cheese Recall Analysis for Pharma

The FDA and CDC are investigating a Listeria outbreak linked to soft cheese recalls from Clover Hill Dairy and RAW FARM, LLC. This analysis covers the regulatory timeline, affected products, and strategic implications for pharmaceutical business development and investment teams.

Amish Health Beliefs: Vaccines, Costs, and Pharma Strategy Insights

This article analyzes Amish health behaviors, including low vaccination rates and selective medical care use, and their implications for pharmaceutical strategy and public health engagement.